A detailed history of Rafferty Asset Management, LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 89,498 shares of AGIO stock, worth $4.98 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
89,498
Previous 76,853 16.45%
Holding current value
$4.98 Million
Previous $3.31 Million 20.01%
% of portfolio
0.01%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$41.19 - $49.72 $520,847 - $628,709
12,645 Added 16.45%
89,498 $3.98 Million
Q2 2024

Aug 13, 2024

SELL
$27.55 - $48.83 $3.98 Million - $7.05 Million
-144,356 Reduced 65.26%
76,853 $3.31 Million
Q1 2024

May 13, 2024

BUY
$21.32 - $34.81 $1.44 Million - $2.36 Million
67,724 Added 44.12%
221,209 $6.47 Million
Q4 2023

Feb 13, 2024

BUY
$19.97 - $24.53 $396,624 - $487,190
19,861 Added 14.86%
153,485 $3.42 Million
Q3 2023

Nov 13, 2023

SELL
$24.36 - $28.18 $730,385 - $844,920
-29,983 Reduced 18.33%
133,624 $3.31 Million
Q2 2023

Aug 11, 2023

SELL
$21.38 - $29.19 $909,462 - $1.24 Million
-42,538 Reduced 20.63%
163,607 $4.63 Million
Q1 2023

May 11, 2023

SELL
$21.74 - $30.93 $119,830 - $170,486
-5,512 Reduced 2.6%
206,145 $4.74 Million
Q4 2022

Feb 13, 2023

BUY
$24.81 - $31.52 $1.88 Million - $2.38 Million
75,665 Added 55.64%
211,657 $5.94 Million
Q3 2022

Nov 14, 2022

BUY
$19.51 - $34.14 $326,480 - $571,298
16,734 Added 14.03%
135,992 $3.85 Million
Q2 2022

Aug 12, 2022

SELL
$17.06 - $31.42 $999,733 - $1.84 Million
-58,601 Reduced 32.95%
119,258 $2.64 Million
Q1 2022

May 13, 2022

SELL
$26.68 - $34.81 $11,018 - $14,376
-413 Reduced 0.23%
177,859 $5.18 Million
Q4 2021

Feb 10, 2022

BUY
$29.58 - $49.78 $3.23 Million - $5.44 Million
109,293 Added 158.44%
178,272 $5.86 Million
Q3 2021

Nov 10, 2021

BUY
$41.92 - $58.18 $997,696 - $1.38 Million
23,800 Added 52.68%
68,979 $3.18 Million
Q2 2021

Aug 10, 2021

SELL
$52.06 - $61.27 $1.01 Million - $1.19 Million
-19,400 Reduced 30.04%
45,179 $2.49 Million
Q1 2021

May 10, 2021

BUY
$44.23 - $57.5 $1.63 Million - $2.12 Million
36,924 Added 133.52%
64,579 $3.34 Million
Q4 2020

Feb 10, 2021

SELL
$33.21 - $46.54 $863,991 - $1.21 Million
-26,016 Reduced 48.47%
27,655 $1.2 Million
Q3 2020

Nov 13, 2020

BUY
$33.87 - $55.93 $1.13 Million - $1.87 Million
33,414 Added 164.95%
53,671 $1.88 Million
Q2 2020

Aug 07, 2020

BUY
$34.45 - $53.48 $456,496 - $708,663
13,251 Added 189.14%
20,257 $1.08 Million
Q1 2020

May 15, 2020

SELL
$31.52 - $53.81 $1.65 Million - $2.82 Million
-52,449 Reduced 88.22%
7,006 $249,000
Q4 2019

Feb 10, 2020

SELL
$30.08 - $50.59 $1.7 Million - $2.86 Million
-56,518 Reduced 48.73%
59,455 $2.84 Million
Q3 2019

Nov 14, 2019

BUY
$32.4 - $49.58 $831,967 - $1.27 Million
25,678 Added 28.44%
115,973 $3.76 Million
Q2 2019

Aug 09, 2019

BUY
$46.17 - $68.1 $1.03 Million - $1.52 Million
22,307 Added 32.81%
90,295 $4.5 Million
Q1 2019

May 15, 2019

BUY
$45.92 - $67.67 $3.12 Million - $4.6 Million
67,988 New
67,988 $4.59 Million

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $3.05B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.